

- Abetalipoproteinemia (Bassen- Kornzweig disease), 408
 Accessory deep peroneal nerve, 21
 Acid ceramidase, 430t, 448, 449f
 Acid mucopolysaccharide, 116, 184, 300
 Acromegaly, 332t, 344
 Acrylamide, neuropathy with, 56, 58, 60, 147t, 358t, 370, 413
 Acute inflammatory demyelinating neuropathy (AIDP).
See Guillain-Barre syndrome
 Acute leukemia, 152t, 155, 273, 274t, 317, 323, 324f
 Acute neuritis, leprosy 238, 239f, 240f
 Adrenoleukodystrophy 101t, 138t, 140t, 154t, 155t, 156t, 430t
 clinical manifestations, 451
 electron microscopy, 452
 light microscopy, 451
 lipofuscin, Schwann cells, 92
 pathology, 451-454
 Adrenomyeloneuropathy (AMN), 140t, 154t, 451-454, 452f, 453f, 454f, 462t
 Adriamycin. *See* Doxorubicin
 Adult polyglucosan body disease, 3t, 74f, 140t, 154t, 460, 472-474, 473f
 Adult T-cell lymphoma/leukemia (ATLL), 217, 318, 323
 Adulterated rapeseed oil, 134t, 205, 370
 Age-related changes, peripheral nerves, 8, 36-39
 AIDS. *See* HIV-associated neuropathy
 Albumin blood-nerve barrier, 115-117, 156t
 endoneurial interstitium, 33
 Alcoholic neuropathy
 clinical manifestations, 348
 pathogenesis, 349-350
 pathology, 348
 Aldose reductase
 inhibitors, 332, 341-343, 342t
 pathway, 341-3
 Allergic neuritis. *See* Experimental allergic neuritis
 Allopurinol, neuropathy and, 356t, 370
 Almitrine, neuropathy and, 356t
 α -neuraminidase, 430t, 461
 Amiodarone neuropathy
 case example, 362
 differential diagnosis, 360
 pathogenesis, 360
 pathology, 3t, 5t, 101t, 138t, 140t, 154t, 356t, 357-362, 359f, 360f, 361f, 362f
 Amitriptyline, neuropathy and, 356t
 Amphiphilic drugs, 135, 140t, 144, 355, 357t, 360 *See also*
 Amiodarone; Chloroquine
 Amyelinating neuropathy, 403
 Amyloid neuropathy
 apolipoprotein A1, 8t, 155t, 296-297
 biopsy sites, 298
 case example, 307
 classification, 295
 clinical manifestations, 295-297
 differential diagnosis, 306
 familial, 296
 gelsolin, 296
 immunohistochemistry, 300
 pathogenesis, 305
 pathology, 147, 298-305, 299f, 300f, 301f, 302f, 303f, 304f, 305f
 "sporadic," 297
 staining techniques 300
 transthyretin 296, 303f, 304f, 305f
 usefulness of biopsy, 295
 Amyloidosis
 classification, 295-297
 dialysis, 295
 primary, 295-296
 secondary, 298
 treatment, 297
 Amyotrophic lateral sclerosis (ALS), 476
 Analphalipoproteinemia, 457-459
 Andersen disease, 460
 Angiocentric lymphoproliferative lesions, 200, 209, 215, 264
 Angioimmunoblastic lymphadenopathy, 7t, 326
 Angiokeratoma corporis diffusum (see Fabry Disease)
 Angiotropic lymphoma, 318, 322f, 323f
 Antabuse. *See* Disulfiram neuropathy
 Antibodies
 anti-chondroitin sulfate, 282, 287
 anti-GM1, 171, 173, 192
 anti-Hu, 156t, 311-315, 313f
 anti-MAG, 3t, 8t, 156t, 274, 275, 278, 283-286, 280f, 285f, 286f
 Antigen-presenting cells, macrophages as, 31
 Apolipoprotein A1, 296
 Arsenic, 153t, 174, 355, 358t
 Arterioles. *See* Peripheral nerve vasculature
 Arthropod stings, 219, 245t
 Artifacts. *See* Peripheral nerve biopsy, artifacts
 Arylsulfatase A, 156t, 429-436, 430t, 432f, 433f, 434f, 435f
 Ataxia syndromes, hereditary, 406-408
 Ataxia telangiectasia, 60, 147, 155t, 415
 Atrophy, axonal. *See* Axonal atrophy
 Autosomal recessive CMT-1 with basal lamina onion bulbs, 375, 381, 400
 Autosomal recessive CMT-1 with focally folded myelin, 381, 383, 385, 391, 401, 402f, 403
 Autosomal recessive CMT-3 with basal lamina onion bulbs, 398-400, 400f, 401f
 Axoglia dysjunction, 333, 341, 343
 Axon-Schwann cell interactions, wallerian degeneration, 63-72
 Axon-Schwann cell networks, 61f, 72-73, 102, 369, 416, 458
 Axonal atrophy
 identification of, 59, 59f
 with secondary demyelination 94, 101-102
 Axonal degeneration
 dissolution of axoplasm, 64, 65f
 distal axonopathy, 56
 Guillain-Barre syndrome, 167, 168
 histogram analysis, 47f
 microscopy, 58-61, 136
 morphometry, 44-48
 non-specific biopsy findings, 44
 peripheral nerve ischemia, 117-118
 wallerian degeneration, 63-72
 Axonal diameter. *See also* G-ratio
 as determinant of conduction velocity, 89, 155
 ranges, myelinated /unmyelinated fibers, 156
 regulation of, 56
 Axonal inclusions
 electron microscopy, 144-146
 neuroaxonal dystrophy, 144, 397-400, 418f, 419f, 420f
 Niemann-Pick disease, 444
 paracrystalline filamentous aggregates, 75
 polyglucosan bodies (PGBs), 74, 74f
 Axonal neuropathy
 differential diagnosis, 153t
 electrophysiological findings, 156-158
 Axonal regeneration. *See also* Regenerating clusters
 histologic hallmarks, 75-80, 76f, 77f, 78f, 79f, 80f
 light microscopy, 76f, 79f
 mechanisms, 75-77

- Axonal swelling and neurofilament accumulations
 differential diagnosis, 58, 146-147, 147t
 giant axonal neuropathy 408-413, 409f, 410f, 411f, 412f
 as non-specific indicator of axonopathy 58, 58f
 toxic causes 362, 366f, 368, 365f, 356t, 357t, 358t
- Axonal transport
 normal mechanisms, 54-56
 pathologic changes 57-58
- Axonopathy
 age-related, 38-39
 clinical features, 56, 355
 defined, 51
 etiologies, 56
 mechanisms, 50-51
 microscopy, 56-61, 58f, 59f, 60f, 61f, 62f
 with secondary demyelination, 101-102
- Axons. *See also* Myelinated fibers (MPs); Unmyelinated fibers (UFs)
 cytoskeleton, 51-53, 52f
 granular material, 53
 identifying within Schwann cell subunits, 28-29
 at node of Ranvier 52f, 53f, 54f, 137f
 ultrastructure, normal, 51-54, 52f, 53f, 54f
- Axoplasmic reticulum, 53
- B1 deficiency, 332, 346-347
 "Banana" bodies, 448, 449f,
 Bands of Büngner, 68, 73, 140, 144t, 281
 Basement membrane
 fragmentation, following wallerian degeneration, 68, 78f
 perineurium, 22
 Schwann cells, 48, 68
 ultrastructural changes in diabetic neuropathy, 333-334
 ultrastructural changes with aging, 38
- Bassen-Kornzweig disease, 408
 Batten-Kufs disease, 140t, 448, 454-457, 456f
 Behçet disease, 245t, 247, 356t, 357t
 "Benign" paraproteinemia, 273
 Beriberi. *See* Thiamine (B1) deficiency neuropathy
 Bielschowsky bodies, 74f, 74. *See also* Polyglucosan bodies
 Biliary cirrhosis, primary, neuropathy in. *See* Liver disease
 Biological toxins, neuropathy and, 355, 356t, 357t, 358t
 Biopsy, nerve. *See* Peripheral nerve biopsy Blood-nerve barrier
 anatomic substrate, 114-115
 in Guillain-Barre syndrome, 174
 pathological states, 114-117
 in wallerian degeneration, 72-73, 117
- Borderline leprosy
 clinical manifestations, 227
 pathology, 236, 238f
- Brachial plexus neuropathy
 in HNPP 385
 hypertrophic, 190, 190f, 191f
 inherited recurrent, 392-393
- Brancher deficiency, 430t, 460, 472
 Bruns-Garland syndrome, 332, 332t, 338, 340f
 Buckthorn, neuropathy 358, 370
 Büngner, bands of. *See* Bands of Büngner
- Calcification, perineurium, 24, 24f
 Calcium
 axonal transport and, 54-56
 demyelination mechanisms, 102
 in perineurium 26f, 133-134
- Calcium oxalate crystals, 418-419, 420f
 Campylobacter jejuni, in GBS, 162, 173-174, 192
 Cancer. *See* Neoplasia-associated neuropathy
 Capillaries. *See* Endoneurium microvessels
 Carbon disulfide, 58, 147t, 3358t, 363, 365f, 366f, 413
 Carpal tunnel syndrome, 215, 248, 295, 296, 344
 Castleman disease, 133, 155t, 274, 325-326
 Cell types, infiltrates, 130t
 Cerebellar ataxia, 155t, 406
 Cerebello-olivary (Holmes type) degeneration, 407
 Cerebrotendinous xanthomatosis, 406, 430t, 459-460, 462t
 Ceroid-lipofuscinosis, neuronal. *See* Batten-Kufs disease
 Chagas disease, 8t, 134t
 Charcot-Leyden crystals, 250, 257f, 258f
 Charcot-Marie-Tooth Neuropathies
 353, 354t
- Charcot-Marie-Tooth (CMT-1)
 classification, 375
 clinical features, 377
 differential diagnosis, 384
 distinction from CIDP, 187
 fiber teasing, 381
 light microscopy, 377, 378f
 morphometry, 47
 onion bulbs, 377-381, 378f, 380f, 381f, 382f, 383f
 pathology, 377-383, 378f, 380f, 381f, 382f, 383f
 type 1A (CMT-1A) 376
 type 1B (CMT-1B) 384
 usefulness of biopsy, 377
 variants, 381-382
 X-linked, 384
- Charcot-Marie-Tooth 2 (CMT-2)
 clinical manifestations, 393-394
 differential diagnosis, 394
 pathogenesis, 394
 pathology, 394
- Charcot-Marie-Tooth 3 (CMT-3)
See Congenital dysmyelinating neuropathies
- Charcot-Marie-Tooth 4 (CMT-4).
See Refsum disease (CMT-4)
- Charcot-Marie-Tooth 5 (CMT-5) 404-405
 Charcot-Marie-Tooth 6 (CMT-6), 404-405
 Charcot-Marie-Tooth 7 (CMT-7) 404-405
 CMT, intermediate. *See* Intermediate CMT neuropathy
 CMT-X linked, 384
 Chediak-Higashi syndrome, 139, 147, 408
 Chloramphenicol, neuropathy, 152t, 356t
 Chloroquine neuropathy, 356t, 360, 362f, 363f
 Cholestanolosis. *See* Cerebrotendinous xanthomatosis
 Cholesterol embolus syndrome, 133, 245t, 251
 Chondroitin sulfate
 antibodies against, 282, 287
 in endoneurium, 33, 285
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
 biopsy findings, 175-187
 blood-nerve barrier, 184
 clinical manifestations, 174-175
 differential diagnosis, 187-188
 diseases associated with, 175
 distinguishing from CMT-1, 187, 187f, 376, 377, 384-385
 distinguishing from vasculitic neuropathy, 264
 fiber teasing, 184-185
 immunohistochemistry, 185
 macrophage mediated demyelination (MMD), 96

- morphometry, 176-177
multifocal neuropathy with persistent conduction block, 190, 190f, 191f
paraprotein associated, 175
pathogenesis, 186-187
pathology, 175-187
treatment, 175
usefulness of biopsy, 175-176
- Chronic lymphocytic leukemia (CLL), 318
- Chronic vascular insufficiency, 119
- Churg-Strauss angiitis (eosinophilic granulomatosis with polyangiitis), 134t, 153t, 154t, 200, 245t, 247, 255, 257f, 258f, 476
- CIDP. *See* Chronic inflammatory demyelinating polyradiculoneuropathy
- Cis-platinum, neuropathy and, 357t
- "Cluster ratio," 41, 364-365. *See also* Regenerating clusters
- CMV. *See* Cytomegalovirus-associated (CMV) neuropathy
- Cobalamin deficiency, 332t, 347-348
- Cockayne syndrome, 414-415
- Colchicine, neuropathy 28, 57, 356t, 367
- Collagen
aging changes, 38-39
in endoneurium, 25, 32
in epineurium, 22
in neuropathy, 32
in perineurium, 22-23, 25f
pockets 28, 29, 29f
- Complement
and blood-nerve barrier, 184
CIDP pathogenesis, 186
demyelination, 96, 102, 171, 284
GBS pathogenesis, 171-174
immunohistochemistry, 148
- Compound muscle action potential (CMAP), 156-157, 157t, 188
- Conduction velocity. *See* Nerve conduction studies (NCS)
- Congenital dysmyelinating neuropathies (CDN) also known as CMT-associated demyelinating neuropathies of early onset
with amyelination, 402
basal lamina onion bulbs, 399-400
classification, 398, 400f, 401f
clinical manifestations, 398
- Dejerine-Sottas syndrome. *See* Dejerine-Sottas syndrome
distinguishing from CMT-1, 391-392
- electron microscopy, 398-399, 400f, 401f
- focal myelin abnormalities, 402
- globular neuropathy, 101, 383, 390, 391
- neuropathy with unstable myelin (NUM), 101, 383, 390, 391
pathogenesis, 399-340
pathology, 399-400
- Congo red staining, 302f
- Cori-Forbes disease, 430t
- Corneal "whorl" dystrophy, 439t
- Corpora amylacea, 74. *See also* Polyglucosan bodies
- Creutzfeldt-Jakob disease, 154t, 220
- Critical illness polyneuropathy, 153t, 155t, 475t, 476-477
- Crohn disease, 348, 357t
- Crush artifact, 97, 128f, 261f,
- Cryoglobulinemic neuropathy
clinical manifestations, 288
electron microscopy, 288-299
light microscopy, 288
pathogenesis, 289
pathology, 288-289
- Cryptogenic peripheral neuropathy, 2
- Cuffing. *See* Perivascular cuffing
- "Curvilinear" inclusions, 447, 448, 452, 455, 456f, 457, 461
- Cyanide, neuropathy with, 358t, 370
- Cytokines
in axonal regeneration, 73
in Castleman's disease, 325
in Guillain-Barre syndrome, 171
- Cytomegalovirus-associated (CMV) neuropathy
HIV and, 212f, 213f, 215
- pathogenesis, 216
- pathology, 212f, 213f, 215
- Cytoskeleton, axon, 51-52
- Dapsone, neuropathy and, 153t, 228, 356t
- Ddl/ddC, neuropathy and, 209, 215, 356t
- Deep peroneal nerve, accessory, 8, 21, 46t
- Degranulation, mast cells, 31, 115, 174
- Dejerine-Sottas syndrome (CMT-3). *See* Congenital dysmyelinating neuropathies
clinical manifestations, 398
distinguishing from CMT-1, 391-392
myelin protein mutations, 399
pathogenesis, 399-400
pathology, 399-400, 399f, 400f, 401f
- Demyelinating neuropathies
etiology, 154t
onion bulbs, 138t
Schwann cell inclusions, 101t
usefulness of nerve biopsy, 6, 7
- Demyelination. *See also* Remyelination; Onion bulbs;
associated with abnormal myelin periodicity, 97-100, 98f, 99f
associated with Schwann cell inclusions, 101, 93f
biopsy assessment for, 137-138
electrophysiology 155-158
macrophage mediated, 96, 165f, 170f, 169f
mechanisms of, 102
- Demyelination (continued)
non-specific features of, 69f, 95, 95f
primary, 94
secondary, 94, 101-102
teased fibers, detection of, 43-44
vesicular, 69f, 96-97, 95f
- Denervated Schwann cell subunit (ScSu) defined, 29
electron microscopy, 142, 141f, 142f
identification, 48
as indicator of UF loss, 48, 142
normal biopsy findings, 27f, 48
- Dense bodies, axonopathy, 54, 54f, 60, 68f, 414, 417, 420f, 447
- Diabetic amyotrophy. *See* Diabetic neuropathy, asymmetric
- Diabetic lumbosacral plexopathy. *See* Diabetic neuropathy, asymmetric
- Diabetic neuropathy, asymmetric clinical features, 332
pathology, 338
- Diabetic neuropathy, symmetric
axoglial dysjunction, 333, 341, 343
blood-nerve barrier, 184,
clinical manifestations, 331-332
demyelination, 3332t, 332-333, 337f
focal nerve lesions, 335, 333, 336
light microscopy, 333-340
onion bulbs, 332-333
pathogenesis, 341-344
pathology, 332-341, 334f, 335f, 336f, 337f, 338f, 339f, 340f
peripheral nerve ischemia, 117-118
small-fiber neuropathy, 335, 340
vascular alterations, 338-340, 339f

- Diabetic polyradiculopathy. *See* Diabetic neuropathy, asymmetric
Dialysis amyloidosis, 295, 347
Dimethylaminopropionitrile, 60, 136t, 355, 358t
Diphtheric polyneuropathy, 102, 103, 153t, 154, 154t, 219-220, 355, 358t, 370
Distal axonopathy. *See* Axonopathy
Distal symmetrical polyneuropathy in HIV infection (DSPN)
 clinical manifestations, 211
 pathology, 211
 pathogenesis, 213-214
Disulfiram (Antabuse) neuropathy, 362-335, 365f, 366f
DNA repair, defective, 414, 415
Doxorubicin, neuropathy and, 356t
DSPN. *See* Distal symmetrical polyneuropathy in HIV infection
"Dying-back" axonopathy. *See* Axonopathy
Dynein, 55
Dysproteinemic neuropathies. *See* Paraproteinemic neuropathy

EAN. *See* Experimental allergic neuritis
Edema, endoneurial
 blood-nerve barrier, 184, 344
 CIDP, 116, 177, 184, 186f
 vacuolated fibroblasts and, 147
Edema, subperineurial, 347, 350, 33
Elastic fibers. *See also* Oxytalan
 in endoneurium, 25, 33
 in epineurium, 22
Elaunin, 33, 34f, 147, 280, 284f
Electrocoagulation artifact, 125t, 131f
Electromyography (EMG), 155
Electron microscopy
 artifacts, 125t
 axonopathy, non-specific features, 56-63
 detection of myelin changes, 140-147
 for assessment of unmyelinated fibers, 140
 technique, 123-124
Electrophysiological testing, 155-158
Elzholz bodies (Mu granules), 89, 92, 93f
Endocarditis, neuropathy in, 153t, 245t, 477
Endocrine disease. *See* Metabolic neuropathies, acquired
Endoneurial matrix, 32-33
Endoneurium
 age-related changes, 36-39
 area, 47
 blood-nerve barrier, 114-117, 184
 cells, 22
 collagen, 32-33
 contents, 25-33, 47
 definition, 25
 macromolecules, 32
 microvessels, 111-113, 114f, 115f, 116f
 pressure, 25
 wallerian degeneration, 63-72
Endothelial cells, fenestration, 115, 16, 116f, 184, 186f, 281, 300
Eosinophilia myalgia syndrome, 134t, 138t, 154t, 245t, 261
Eosinophilic fasciitis, 369-370
Eosinophilic infiltration
 differential diagnosis, 255
 eosinophilia-myalgia syndrome, 369-370
 hypereosinophilic syndrome, 475-476
Epidemic toxic inflammatory neuropathies, 369-371
Epineurium
 Assessment of biopsy, 127-33
 blood-nerve barrier, 114-115
 contents, 22
 microscopic architecture, 22, 23f
 vasculature, 114-115, 127
 in vasculitis, 249
Epithelioid histiocytes
 appearance, 198, 198f, 200f
 differential diagnosis, 134t
Erythema nodosum leprosum (ENL), 226, 238, 240f, 245t, 249
Ethambutol, neuropathy and, 4t, 356t
Ethylene oxide, neuropathy 59, 152t, 358t
Experimental allergic neuritis (EAN), 32, 90, 97, 98t, 99t, 170, 174, 186
Extrinsic neural vascular system, 111

Fabry disease
 case example, 442-443
 clinical manifestations, 439-440
 Maltese cross, 135, 360, 439, 439f, 444
 pathology, 439-444, 439f, 440f, 441f, 443f, 443f,
Familial amyloid neuropathy. *See* Amyloid neuropathy,familial
Farber disease (lipogranulomatosis), 448-449, 449f, 450f, 462t
Fascicular anatomy, light microscopy, 127
Fascicular biopsy, 9, 249, 300, 392
Fenestration, endoneurial vessels, 115, 116, 116f, 184, 186f, 281, 300
Fiber density
 aging changes, 38,46t
 normal, 46t
Fiber teasing
 CIDP, 184-185
 Hereditary neuropathies with pressure palsies (HNPP), 391, 390f
 CMT-1, 381
 quantitative analysis, 43-44
 secondary demyelination, demonstration of, 101-102
 specimen preparation, 124
 usefulness, 43-44, 148
Fibroblasts
 endoneurium, 117
 epineurium, 22
 microscopic appearance 30, 30f
 perineurial cells derived from, 24
 proliferation, wallerian degeneration, 68-69
 Renaut bodies and, 33
 vacuolated, 38, 38f
Fibronectin, endoneurium, 33
Fibrosis
 in leprosy, 229
 mast cells, role of, 31
Filopodia, 75
"Fingerprint" inclusions, 455, 456f, 461
FK506, neuropathy and, 356t
"Foamy cells"
 in leprosy 228, 230f
 in Niemann-Pick disease, 444-447, 445f, 446f, 447f
 in perineuritis, 201-205, 203f, 204f, 205f
 in wallerian degeneration, 68, 67f, 68f, 71f
Focal nerve compression, Renaut bodies and, 33
Focal nerve ischemia, 117
Focal nerve lesions
 diabetic neuropathy, 333, 334f
 in experimental ischemia, 118
 significance, 139
 in vasculitis, 117, 251-249
Focally folded myelin, 381, 383, 385, 391, 401, 402
Folate deficiency, 348
Friedreich ataxia, 384, 406-407
Frozen biopsy sections, 124

- G-ratio
 defined, 46
 in Dejerine-Sottas syndrome, 401
- Galactosylceramidase, 436
- Galactosylceramide-[3-galactosidase deficiency (Krabbe leukodystrophy), 436-437, 462t
- Ganglioside-[3-galactosidase deficiency (GM1 gangliosidosis), 430t, 451, 462t
- Gangliosidosis, 429, 430t, 449- 451, 461
- Gaucher disease, 451
- Gelsolin, 154t, 155t, 296-297, 300
- Genetically determined neuropathies 375-421
 electrophysiology, 158
 usefulness of biopsy, 5-10
- "Ghost" bodies, 134
- "Ghost" vessels, 147
- Giant axonal neuropathy
 biopsy site, 409-410
 clinical manifestations, 408
 differential diagnosis, 413
 pathogenesis, 412
 pathology, 409, 409f, 410f, 411f, 412f
 toxic neuropathies and, 370
- Giant cell (temporal) arteritis, 245t, 248, 250
- Giant vacuolated fibroblasts, 30, 30f, 117, 147
- Glycogen. *See also* Polyglucosan bodies
 axonal, 61, 64f
 storage diseases, 460
- Glycolipids
 myelin, 89
 paraproteinemic neuropathy, antigenic targets, 283
- Glycoproteins, myelin, 89-90
- Glyoxylate metabolism (primary hyperoxaluria), 418-419, 420f
- GM, gangliosidosis, 429, 430t, 449-451, 461
- GM2 gangliosidosis, 429, 430t, 449-451, 461, 462t
- Gold, neuropathy 355, 356t, 370
- Granular disintegration, axon. *See* Wallerian degeneration
- Granular material, axons, 53
- Granuloma, sarcoid, 197, 198f, 199f
- Granulomatosis, lymphomatoid, 264-268
- Granulomatous neuropathy, 3t, 58, 134t, 370
- Greater auricular nerve, 8
- Growth cones, axonal regeneration, 75-80, 76f, 77f, 78f, 79f, 80f
- Guillain-Barre syndrome (GBS)
 Acute Inflammatory Demyelinating Polyneuropathy AIDP), 161
 Antibodies and complement, 171-172
 "Axonal GBS" Acute Motor Axonal Neuropathy [AMAN] 164, 173f
 blood-nerve barrier, 174
 clinical manifestations, 161-162
 in HIV infection, 214
 with Hodgkin disease, 316
 immunohistochemistry, 168
 lymphocytes, 170-171
 macrophage mediated demyelination (MMD), 163-164, 165f, 168, 169f, 170f, 172f
 pathogenesis, 169
 pathology, 163-164, 165f, 168, 169f, 170f, 172f, 173
 sarcoidosis and, 199
 usefulness of biopsy, 162
- Heavy metals, toxic neuropathy, 356t
- Hemorrhage, intraneuronal, 125t, 139, 249, 250f, 251, 253f, 255t, 256f, 264, 323
- Henoch-Schonlein purpura, 245t, 247
- Hepatitis B infection, 246, 254, 346
- Hereditary ataxias with peripheral neuropathy, 155t, 406-408
- Hereditary neuropathy with pressure palsies (HNPP)
 Case presentation 392
- Clinical manifestations, 385-386
 differential diagnosis, 391-392
 fiber teasing, 390, 390f
 inherited recurrent brachial plexus neuropathy, 392
 light microscopy, 386
 pathogenesis, 391
 pathology, 386-391, 387f, 388f, 389f, 390f
 uncompacted myelin, 386, 389
 without myelin tomaculae, 391
- Hereditary sensory and autonomic neuropathies (HSAN), 405
- Hereditary tyrosinemia. *See* Tyrosinemia, hereditary
- "Herringbone" inclusions (metachromatic leukodystrophy), 124, 431
- Hexacarbon neuropathy, 3t, 56, 57, 58, 358t
- Hexosaminidase deficiency, 430t, 449
- Histamine, mast cell synthesis, 31
- Histograms, morphometry, 45-49, 47f
- Histological classification of neuropathic process, 135-139
- HIV-associated neuropathy
 CMV and, 212f, 215-216
 differential diagnosis, 216
 distal symmetrical polyneuropathy (DSPN), 211-214
 epidemiology, 209
 GBS and, 214
 inflammatory demyelinating polyneuropathy, 214
 mononeuropathy multiplex, 214-215
 syndromes of, 209, 209t
 tubuloreticular inclusions (TRIs), 211f, 213-214
 usefulness of biopsy, 216
 vasculitic neuropathy, 210f, 211f, 214
- Household toxins, neuropathy and, 358t
- HTLV-1 infection, neuropathy and, 217, 323
- Hyalinization, endoneurial microvessels, 333, 334f
- Hyaluronic acid, endoneurial interstitium, 33
- Hydralazine, neuropathy, 347, 356t
- Hypereosinophilic syndrome (HES) neuropathy, 475-476
- "Hypermyelination," 386, 389f, 391, 392, 402
- Hyperosmolar artifact, 125t, 132f
- Hyperoxaluria, neuropathy and, 418-419, 420f
- Hypersensitivity vasculitis clinical manifestations, 245t, 248, 254, 255, 326
- Hyperthyroidism, neuropathy and, 332t, 344
- Hypertrophic hereditary motor and sensory neuropathy (HMSN). *See* Charcot-Marie-Tooth-1 (CMT-1)
- Hypertrophic nerves, 132t
- Hypobetalipoproteinemia, 408
- Hypomyelinating neuropathy, 100, 138
- Hypothyroid neuropathy, 36, 61, 93, 138t, 152t, 153t, 154t, 155t, 332, 344
- Hypoxemia, chronic neural, 120
- Idiopathic perineuritis. *See* Perineuritis, idiopathic
- IgA. *See* Immunoglobulins
- IgG. *See* Immunoglobulins
- IgM. *See* Immunoglobulins
- IgM paraproteinemic neuropathy. *See also* Paraproteinemic neuropathy
 compared to IgA/IgG proteinemic neuropathy, 273
 deposition in endoneurium, 278, 279f, 280, 283, 283f, 284
 hypermyelination, 386
 pathogenesis, 283-285
 pathology, 275-288, 276f, 277f, 279f, 280f, 281f, 283f, 284f, 285f, 286f
 widely spaced myelin, 3t, 5t, 97, 97f, 99f, 99-100, 142, 235, 275, 278, 280f, 286, 287

- Immunofluorescence, 285f
- Immunoglobulins. *See also* Paraproteinemic neuropathy
- blood-nerve barrier, 115-116
 - in endoneurium, 147-148
 - in Guillain-Barre syndrome, 171
 - on Schwann cells, in GBS/CIDP, 168
- Immunohistochemistry
- amyloid neuropathy, 300
 - CIDP, 185
 - Guillain-Barre syndrome, 168
 - lymphomatous neuropathy, 318
 - for macrophages, 30
 - usefulness of, 147
 - in vasculitic neuropathies, 252
- Inclusions. *See also* Axonal inclusions; Endoneurial inclusions; Schwann cell inclusions; Storage diseases;
- Tubuloreticular inclusions
 - adrenoleukodystrophy, 101t, 138t, 140t, 154t, 155t, 156t, 430t
 - Batten-Kufs disease, 140t, 448, 454-457, 456f
 - cerebrotendinous xanthomatosis, 406, 430t, 459-460, 462t
 - Cockayne syndrome, 414-415
 - Differential diagnosis in storage diseases, 462t
 - Fabry disease, 437-444
 - Farber disease, 448, 449f, 450f
 - Krabbe disease, 436-451, 437f, 438f, 462t
 - metachromatic leukodystrophy, 429-436, 432f, 433f, 434f, 435f
 - Niemann-Pick disease, 444-447, 445f, 446f, 447f
 - Refsum disease, 413
 - Indeterminate leprosy, 237
 - Infection, post-biopsy, 9
- Infectious diseases causing neuropathy. *See also* HIV-associated neuropathy; HTLV-1 associated neuropathy; Leprous neuropathy; Lyme neuropathy
- Chagas disease, 8t, 134t
 - Creutzfeldt-Jakob disease, 154t, 220
 - diphtheric polyneuropathy, 219-220, 355, 358t, 370
- Infiltrative neuropathy
- leukemia, 318
 - lymphoma, 317
 - lymphomatoid granulomatosis, 264-268
 - multiple myeloma, 323
- Inflammatory demyelinating neuropathies. *See* Guillain-Barre syndrome; CIDP
- Inflammatory neuropathies
- blood-nerve barrier alteration, 115
 - differential diagnosis, 134t
 - endoneurial "edema," 117
 - epidemic toxic, 369-371
- Inhalant abuse, 368
- Inherited neuropathy. *See* Genetically determined neuropathies
- Insect bites, 161, 219
- Interleukin-1 (IL-1), 73
- Interleukin-2 (IL-2), 170, 187, 198
- "Intermediate" CMT, 394
- Internodal length (IL)
- alterations of, 37
 - in axonal regeneration, 79
 - determinants of, 89
 - normal values, 27
 - in remyelination, 96-98
- Internode, 12, 12f, 15f, 26-27, 38, 43, 44, 48, 49, 52f, 54
- Intestinal pseudo-obstruction, 312
- Intrapерiod line
- normal, 97
 - separation of, 98-100
 - Intrinsic neural vascular system, 111
- Ischemic injury, peripheral nerves
- cell types affected, 118
 - chronic, 119-120
 - clues to diagnosis, 255
 - in cryoglobulinemia, 153t, 154t, 245t, 249, 255
 - in diabetes, 343-344
 - endoneurial involvement, 118
 - experimental, 118-119
 - fascicular geography, nerve damage, 118
 - focal, 117-118
 - increased endoneurial pressure, cause of 117
 - in leprosy, 240-241
 - resistance to, 113
 - in sarcoidosis, 199
 - secondary demyelination, 253
 - in vasculitis, 250-251
- Isolated PNS vasculitis, 246 *See also* Vasculitic neuropathy
- Isoniazid, 56, 152t, 347, 356t
- "Jelly roll" appearance, hypermyelinated fibers, 387f, 388f, 389f
- Kearns-Sayre syndrome (KSS), 469-471
- Kennedy syndrome, 476
- Kinesin, 55, 358t, 367
- Krabbe disease, 90, 101t, 154t, 156t, 430t, 436-451, 437f, 438f, 462t
- Kufs disease. *See* Batten-Kufs disease
- L-tryptophan, 152t, 154t, 201, 205, 356t, 369, 370
- Laboratory testing, peripheral neuropathies, 155-158, 156t
- Lafora bodies, 74. *See also* Polyglucosan bodies
- Lafora disease, 472
- Lamellipodia, 75
- Laminin, endoneurial matrix, 33
- Lateral sural cutaneous nerve, 8
- Lead neuropathy, 368-369
- Leber hereditary optic neuropathy, 469-471
- Leigh disease, 469-471
- Lepromatous Leprosy
- clinical manifestations, 226
 - pathology, 228-235, 229f, 230f, 231f, 232f, 233f, 234f, 235f
- Leprous neuropathy
- acute neuritis, 228
 - biopsy sites, 228
 - blood-nerve barrier, 240
 - borderline. *See* Borderline leprosy
 - clinical manifestations, 226-228
 - differential diagnosis, 241
 - distinguishing from sarcoidosis 241
 - epidemiology, 225
 - lepromatous. *See* Lepromatous leprosy
 - light microscopy, 228, 235
 - mechanism of nerve injury, 240
 - mechanism of organism spread, 240
 - pathogenesis, 240
 - pathology, 229-239
 - pure (primary) neuritic leprosy, 238, 239f
 - tuberculoid. *See* Tuberculoid leprosy
 - usefulness of biopsy, 228

- Leukemic infiltration, peripheral nerves, 318
- Leukocyte common antigen (LCA). *See* Immunohistochemistry
- Leukocytes
- atypical, 134t, 316
 - immunostaining, 32
 - normal numbers, 32
- Light and heavy chain deposition disease (LHCDD), *See* Paraproteinemic neuropathy
- Light chain deposition disease (LCDD). *See* Paraproteinemic neuropathy
- Light microscopy
- artifacts, 125t, 125f-133f
 - endoneurium, examination of, 135-140
 - epineurium, examination of, 127-133
 - perineurium, examination of, 133-135
 - technique, 123-124
- Lipid, in nerve
- amiodarone neuropathy, 357-362
 - storage diseases, 429-
- Lipid myelin components, 89
- Lipofuscin
- normal, 92
 - in neuropathies, 461
- Lipogranulomatosis. *See*, Farber disease
- Lithium, neuropathy 355, 356t
- Liver disease, neuropathy in, 324
- "Loosened myelin," 100, 434
- "Lorenzo's oil," 453
- Luse bodies, perineurium, 24, 26f
- Lyme disease, neuropathy of, 217-219, 134t, 152t, 153t, 154t, 205, 245t, 249
- Lymphocytes. *See* Leukocytes
- Lymphoma, neuropathy and, angiotropic, 133, 317, 322f, 323f
- Guillain-Barre syndrome, 316
 - Hodgkin disease, 311, 312, 316, 325
 - infiltrative neuropathy, 317
 - paraneoplastic neuropathy, 311-316
 - pathology, 317-318, 313f, 314f
 - perineurial involvement, 317
 - role of nerve biopsy, 317
- Lymphomatoid granulomatosis
- case example, 266
 - clinical manifestations, 264
 - distinguishing from leprosy neuropathy, 241
 - pathology, 265, 267f, 268f
- Lymphomatous neuropathy. *See* Lymphoma
- Macrophage mediated demyelination (MMD)
- differential diagnosis, 96
 - in CMT-1, 381
 - in inflammatory demyelinating neuropathies, 166
 - as a specific mechanism of demyelination, 96
- Macrophages. *See also* Macrophage mediated demyelination; Epithelioid histiocytes
- clearance of myelin debris, 95
 - function, 30
 - microscopic appearance, 30-31, 67f, 71f
 - resident endoneurial, 30
 - in wallerian degeneration, 63, 67f, 71f
- Madelung disease, 155t, 475t, 477, 478f
- Major dense line
- normal, 97
 - widening (uncompacted myelin), 97
- Malignancy. *See* Neoplasia-associated neuropathy
- "Maltese cross" pattern, biopsy findings, 135, 360, 439, 439f, 444
- Mast cells
- appearance, 31, 32, 31f, 32f, 73, 91, 115, 139, 174, 408, 476
 - in neuropathy, 31, 32
- role, 32
- MELAS (myopathy, encephalopathy, lactic acidosis, stroke-like episodes), 469-471
- Mercury, neuropathy and, 153t, 358t
- MERRF (myoclonus epilepsy with ragged red fibers), 469-471
- Mesaxon, 29, 52f, 85, 86f, 89, 92, 97, 99, 202, 391
- Metabolic neuropathies, acquired, 331-350
- classification, 332t
 - distal axonopathy, 56
- Metachromatic leukodystrophy (MLD)
- clinical manifestations, 429-430
 - inclusions. *See* Inclusions, metachromatic leukodystrophy
 - pathogenesis, 435
 - pathology, 430-435, 432f, 433f, 434f, 435f
 - usefulness of biopsy, 430
- Methyl methacrylate, neuropathy and, 358t
- Methyl n-butyl ketone. *See* Hexacarbon neuropathy Metronidazole, neuropathy 152t, 348, 356t, 367, 377
- MGUS. *See* Paraproteinemic neuropathy, MGUS "
- Microfasciculation, 134, 136f
- Microneuromas, peripheral nerve ischemia, 9, 119, 477, 479f
- Microtubules, axons, 51-53
- "Microvasculitis," 132, 211, 248, 249, 338
- Mild terminal neuropathy associated with malignancy, 315
- Misonidazole neuropathy, 356t, 364-367
- Mitochondria
- alterations, non-specific in axons, 59
 - axonal, 53
 - inclusions, non-specific in Schwann cells, 92-94
 - in Madelung disease, 475, 477, 478f
 - in mitochondrial diseases, 469-471
 - clinical manifestations, 469
 - pathology, 470-471
- MNGIE (mitochondrial neurogastrointestinal encephalomyopathy), 469-471
- Monoclonal gammopathy of unknown significance (MGUS). *See* Paraproteinemic neuropathy
- Mononeuropathy multiplex
- differential diagnosis, 153t
 - findings in, 249
 - HIV-associated, 214, 215
 - as manifestation of vasculitic neuropathy, 209
 - paraneoplastic neuropathies and, 318
- Morphometric techniques. *See also* Quantitative data analysis
- diameter-frequency histograms, 44-49, 47f
 - G-ratio, 46
 - internode-length, 48
 - selection of control nerves, 46
 - usefulness, 46
- Motor nerves, biopsy sites and, 8
- Motor neuron diseases, 476
- Mu granules. *See* Elzholz bodies.
- Mucopolysaccharidoses, 460
- Multifocal motor neuropathy. *See* CIDP
- Multifocal neuropathy with persistent conduction block, 190
- Multiple myeloma
- paraproteinemic neuropathy, 273-288
 - neoplastic infiltrative neuropathy, 318
- Multiple symmetric lipomatosis. *See* Madelung disease
- Muscle-nerve biopsy, combined, 8
- Mycobacteria, neuropathy and
 - M. avium intracellulare, 209
 - M. leprae. *See* Lepromatous neuropathy
 - M. tuberculosis, 245t
- Myelin. *See also* Demyelination; Remyelination;
- Uncompacted myelin; Widely spaced myelin
 - artifactual changes, 125t
 - compact, 89
 - composition, 89

degradation, wallerian degeneration, 65, 67f
electron microscopy, 137, 139, 142
focally folded, 401, 402f
internode parameters, determinants of, 89
ovoids, 64, 39, 44, 64, 67f, 68, 69
periodicity, alterations of. *See* Myelin periodicity proteins, 89-90
redundant loops, folds, 101
structure, 89
unstable, neuropathy with (NUM), 398
Myelin-associated glycoprotein (MAG)
IgM "anti-MAG" paraproteinemic neuropathy, 283-288
normal, 89-90
widely spaced myelin, 99, 99t, 280f
Myelin debris, 66f, 68f, 73, 80f
Myelin Po protein. *See* Po protein
Myelin periodicity
normal, 97
uncompacted, 97, 98t, 98f
widely spaced, 97, 99, 99f, 280f
loosened. *See* "Loosened myelin"
Myelin remodeling, 59, 96, 391
Myelin sheath thickness. *See* G-ratio Myelin
wrinkling, 101, 333
Myelinated axons. *See* Myelinated fibers
Myelinated fibers. *See also* Axons
aging changes, 36-38
assessment on biopsy, 135-139
in children, 37, 39
diameter, 26
fiber density, 46t, 47
G-ratio, 46
histogram analysis, 44-49, 47f
regenerating clusters and, 79-80
selective loss, small fibers, 136t, 137f
velocity of conduction, parameters, 155, 158
Myelinating Schwann cells
inclusions, normal, 91-94
internodal structure, 85, 86, 86f
nodal/paranodal structures, 87-89, 88f
Schmidt-Lanterman clefts, 86
Myotonic dystrophy, 419-420
Myxedema. *See* Hypothyroid neuropathy

Na⁺/K⁺-ATPase activity, 341
"Naked" granuloma, 198, 199f
NARP (neuropathy, ataxia, retinitis pigmentosa), 469, 470t
Necrotizing peripheral nerve vasculitis. *See* Vasculitic neuropathy
Neoplasia-associated neuropathy. *See* Infiltrative neuropathy; Paraneoplastic neuropathy;
Castleman disease
Nerve biopsy. *See* Peripheral nerve biopsy
Nerve conduction studies (NCS)
age-related changes, 36-39
correlation with biopsy findings, 158
CMT-1, 376
CMT-2, 393
techniques, 156
in vasculitic neuropathy, 245
Nerve fiber teasing. *See* Fiber teasing
Nerve growth factor, 73, 75
Nervi nervorum, 14-15
Neuroaxonal dystrophy
clinical manifestations, 417
pathogenesis, 418
pathology, 417-418, 418f, 419f, 420f
Neurofilaments
accumulations, axonopathy and, 58, 58f, 60f, 62f, 358t, 365f, 366f,
368. *See also* Giant axonal neuropathy
axons, 51-53, 52f
"Neurokeratin" artifact, 124, 125f, 127f
Neurolymphomatosis. *See* Lymphoma
Neuromas. *See also* Microneuromas
amputation, mast cell proliferation, 31-32
formation post-biopsy, 9
Neuronal ceroid-lipofuscinosis (NCL). *See* Batten-Kufs disease
Neuropathy. *See* Peripheral neuropathy
Neuropathy with unstable myelin (NUM), 101, 383, 390, 391
N-hexane. *See* Hexacarbon neuropathy
Niemann-Pick disease
case example, 447
clinical manifestations, 444
diagnosis, 444
lipofuscin accumulation, 447
neuroaxonal dystrophy, type 2 Niemann-Pick, 447
pathology, 444-448, 445f, 446f, 447f
Nitrofurantoin, neuropathy and, 153t, 355, 356t, 377
Nitrous oxide, neuropathy and, 152t, 347, 357t, 377
Node of Ranvier
axon 52f, 53f, 54f, 137f
demyelination, paranodal, 95-96
Schwann cell, 88f
transnodal myelination, 386
Non-Friedreich inherited spinocerebellar/cerebellar degenerations, 407
Non-Hodgkin lymphoma. *See* Lymphoma
Non-myelinating Schwann cells (NMSCs, Remak cells)
aging changes, 48
defined, 85
lipofuscin accumulation, normal, 92
normal structure/function, 90
unmyelinated axon loss, 48, 140

Occupational toxins, neuropathy and, 358t
Oleic acid, 453
Olivopontocerebellar degeneration (OPCA Menzel type), 407
Onion bulbs
in CIDP, 169
in Dejerine-Sottas syndrome, 398
demyelination-remyelination, 103-105
denervated 379, 383f
in diabetic neuropathy, 333, 335
differential diagnosis, 138t
distinguishing true from "pseudo," 138, 143f, 335f, 338f, 379, 382, 394, 407
formation, 104
in CMT-1, 378f, 380f, 381f, 382f, 383f
"Onion-skin" appearance of perineurium in leprosy, 228, 229f
in perineuritis, 201
Organelles, axoplasmic
aggregations, in axonopathy, 60, 60f
neurofilament accumulations, 58
in wallerian degeneration, 68
Organophosphates, neuropathy and, 358t
Osteosclerotic myeloma. *See also* Paraproteinemic neuropathy biopsy findings, 142, 154t, 274, 274f
POEMS syndrome and, 274
Oxytalan
distinguishing from amyloid fibrils, 34f, 299, 299f, 306, 308
endoneurial "edema," 115

- in endoneurium, 33-34
- in perineurium and subperineurium, 22,33
- in Renaud bodies, 33,35f, 36f, 37f, 38f
- Po protein**
 - in Dejerine-Sottas syndrome, 399
 - in CMT-IB, 362
 - normal, 89-92
 - uncompacted myelin, 97-98, 98f, 98t
- P1 protein**, 89-90
- P2 protein**
 - in experimental allergic neuritis, 170
 - normal, 89-90
- Pacinian corpuscles, in epineurium, 22, 23f
- Paracrystalline structures in axons, 62f, 75
- mitochondrial inclusions, in Schwann cells, 92, 470-471
- Paraneoplastic neuropathy**
 - acute demyelinating neuropathy, 316
 - angioimmunoblastic lymphadenopathy, 326
 - case example, 326
 - differential diagnosis, 316
 - "microvasculitic" neuropathy, 316
 - necrotizing peripheral nerve vasculitis, 316
 - perineuritis, 201
 - sensorimotor, 314
 - subacute sensory, 311, 313f
- Paranodal demyelination, 95
- Paraproteinemic neuropathy.** *See also* POEMS syndrome
 - blood-nerve barrier, 115
 - case examples, 287-288
 - CIDP and, 175, 275, 285-286
 - classification, 273, 274t
 - clinical manifestations, 273-274
 - cryoglobulinemia. *See* Cryoglobulinemic neuropathy
 - differential diagnosis, 285-286
 - diseases associated with, 274t
 - immunoglobulin deposition disease, 275-279, 279f, 287f, 306
 - immunohistochemistry, 281
 - MGUS, neuropathy in, 273-274
 - osteosclerotic myeloma, neuropathy in, 274
 - pathogenesis, 283-285
 - pathology, 275-283, 276f, 277f, 279f, 287f
 - plasmacytoid cells, 276, 276f
 - treatment, 275
 - uncompacted myelin, 278
 - usefulness of biopsy, 275-276
 - Waldenstrom macroglobulinemia, neuropathy in, 274
 - widely spaced myelin, 278, 280f
- PEO (progressive external ophthalmoplegia), 469
- Perhexiline, neuropathy and, 357t
- Perineurial barrier**, 114
- Perineuritis**
 - case example, 205
 - clinical manifestations, 201
 - differential diagnosis, 205
 - paraneoplastic, 201
 - pathogenesis, 205
 - pathology, 201-205, 202f, 203f, 204f, 205f
 - secondary, 201
- Perineurial involvement**
 - differential diagnosis, 134t
 - infiltrative neuropathy, 317, 319
 - primary biliary cirrhosis, 346
 - leprosy, 228-229
- Perineurium**
 - architecture, 22-23, 24f, 25f, 26f
 - barrier properties, 22
 - inflammation, differential diagnosis, 134t
 - vasculature, 111-112
- Peripheral myelin protein (PMP)-22**
 - composition, 89
 - in hereditary neuropathy with pressure palsies, 385
 - in CMT-1A, 376
- Peripheral nerve biopsy.** *See also* Fiber teasing alternative sites, 7
 - artifacts in specimens, 124-133, 126f, 128f, 1230f, 131f, 132f
 - clinicopathologic correlations, 151
 - combined muscle and nerve, 8
 - comparison /correlation with NCS, 158, 158t
 - electron microscopy, 140-147
 - electrophysiologic correlations, 158, 158t
 - fascicular vs whole nerve, 9
 - frozen sections, 124
 - future directions, 9
 - guidelines for use of, 5
 - immunohistochemical techniques, 147
 - light microscopy, 127-140
 - literature data on, 5
 - methods of examination, 123-124
 - onion bulbs, 138t
 - paraffin-embedded sections, 123
 - plastic-embedded sections, 123
 - sequelae, 9
 - specific diagnoses, 3t
 - specimen quality, assessment of, 124-127, 125t
 - usefulness of, 3-5, 5t
- Peripheral nerve vasculature.** *See also* Endoneurium, microvessels
 - blood-nerve barrier, alterations in, 115-116
 - blood-nerve barrier, normal, 114-115
 - chronic hypoxemia, 120
 - chronic vascular insufficiency, 119-120
 - endoneurial contents, involvement of, 118-119
 - focal ischemic injury, 117-118
 - normal structure/function, 111-115
 - pathological alterations, 115-120
 - resistance to ischemia, 113-114
- Peripheral nerves.** *See also* Endoneurium; Epineurium; Perineurium; Axons
 - age-related changes, 36-39
 - cell contents, 29-32
 - development during early life, 37-39
 - enlarged, differential diagnosis, 132t
 - focal ischemic injury, 117-118
 - microscopic architecture, 22-36
 - morphometric study, 44-49
 - normal structure/ function, 21-36
- Peripheral neuropathy**
 - axonal degeneration or demyelination, 154t
 - axonal inclusion, 144-146
 - axonal swelling, 147t
 - biopsy, indications for, 5
 - blood-nerve barrier in, 115-116
 - chronic, endoneurial collagen increase, 32-33
 - classification, 152t, 153t, 154t, 155t
 - clinical approach to, 151-154
 - cryptogenic, 2
 - differential diagnosis, 153t
 - distribution of, 151-152
 - epidemiology, 1

etiologies, 1-2, 155t-156t
granulomatous, 134t
inclusions in, 140t
inflammatory, 134t
laboratory testing in, 155-158, 156t
mild terminal, 315
onion bulb, 138t
predominantly motor, 153t
predominantly sensory, 152t
small fiber, 136t
syndromic classification, 153-154t
temporal course, 152, 153t
type of fiber affected, 136t, 152, 152t, 153t
usefulness of biopsy, 3-4

Perivascular cuffing. *See also* Inflammatory neuropathy
endoneurial vessels, 32, 139
epineurial vessels, 22, 127-129
"microvasculitis" vs cuffing. *See* "Microvasculitis"

Perivascular inflammation, cell types in, 134t
Peroneal muscular atrophy (PMA), 405
Peroneal nerve, 21
Peroneus brevis muscle biopsy, 8
Peroxisomal disorders. *See* Refsum disease; Adrenoleukodystrophy
Pharmaceutical agents, toxic neuropathies, 356t, 357t
Phenytoin, neuropathy and, 357t
Phospholipids, myelin composition, 89-90
Phytanic acid, ex-oxidation, 413-414
Pi granules
adrenoleukodystrophy, Pi-granule-like bodies, 452, 453f, 454f
alterations, biopsy findings, 139
metachromatic leukodystrophy, distinction from storage material, 431
normal appearance, 91, 92f, 93f

Pinocytotic vesicles
endothelial cells, 114f
fibroblasts, 30
perineurial cells, 22-25, 25f

Plastic-embedded biopsy sections, 123-124
PMP-22. *See* Peripheral myelin protein (PMP)-22
Podophyllin, neuropathy and, 357f, 367
POEMS syndrome
Castleman disease, 325-326
clinical manifestations, 274
osteosclerotic myeloma, 274
pathology, 275-281
uncompacted myelin, 97, 98f, 98t

Polyarteritis nodosa. *See also* Vasculitic neuropathy
clinical manifestations, 346-347
differential diagnosis, pathology, 264
pathogenesis, 253
pathology, 249f-265f
usefulness of biopsy, 249

Polyglucosan bodies (PGBs)
adult polyglucosan body disease, 472-474
in aging, 474
axonal inclusions, 473f, 474f
biopsy findings, 473f, 474f
differential diagnosis, 473f, 474f

Polymerase chain reaction (PCR) assays, 9

Polyneuropathy. *See* Peripheral neuropathy
defined, 151
Pompe disease, 460
Porphyria, 153t, 415-417, 416f
Prealbumin. *See* Transthyretin;
Pressure palsies *See* Hereditary neuropathies with pressure palsies
Primary amyloidosis. *See* Amyloidosis, primary
Primary biliary cirrhosis, 152t, 346

Primary demyelination. *See* Demyelination
Primary neuritic leprosy. *See* Leprosy, pure neuritic
"Prismatic" inclusions, 434, 434f. *See also* Metachromatic leukodystrophy
Procarbazine, neuropathy and, 357t
Progressive external ophthalmoplegia. *See* PEO
Progressive systemic sclerosis. *See* Scleroderma
Protagon granules. *See* Pi granules
Proteases, macrophage, 102
Proximal diabetic neuropathy, 338
Proximal spinal muscular atrophies, 476
Pseudo-obstruction, gastrointestinal, 312
"Pseudo" onion bulbs, 144, 143f, 145f, 379, 382, 384, 407
Pure neuritic leprosy. *See* Leprosy, pure neuritic
Pyridoxine (B6) deficiency, 152t, 332t, 347
Pyridoxine excess, 155t, 347

Quantitative data analysis. *See also* Morphometric techniques
endoneurial area/cell counts, 47-48
fiber composition, sural nerve, 26-29
fiber counts, 46-48
fiber teasing, 43-44
G-ratio, 46-47
histograms, 47, 47f
internodal length, 48
myelinated fiber density/numbers, 46t
normal values, other biopsy sites, 46t
normal values, sural nerve, 46t
nucleated cells, sural nerve, 29-30
regenerating clusters, 48
secondary demyelination, demonstration of, 101
unmyelinated fiber density/numbers, 45-46
unmyelinated fiber loss, assessment, 48
usefulness, 49

"Raccoon tail" (long spaced collagen). *See* Luse body
Radial cutaneous nerve, biopsy site 8
Rapeseed oil, adulterated, 134t, 201, 205, 370
Recurrent brachial plexus neuropathy, inherited, 392-393
Refsum disease (CMT-4)
clinical manifestations, 413
mitochondrial inclusions in, 414
pathology, 413-414
pathogenesis, 414

Regenerating clusters
assessment on nerve biopsy, 136-137
cluster-ratio, 394
defined, 79
formation, 79
in CMT-2, 394
in "intermediate" CMT, 394-397
quantitation, 48

Regeneration. *See* Axonal regeneration
Reich Pi granules. *See* Pi granules
Remak cells. *See* Nonmyelinating Schwann cells
Remote vasculitis, clues to, 255t, 259f, 260f. *See also* Vasculitic neuropathy
Remyelination. *See also* Demyelination-remyelination normal, 103-104, 103f
onion bulb formation, 104

Renal failure. *See* Uremic neuropathy
Renaut bodies
distinguishing from amyloid deposits, 298-300, 299f
endoneurial "edema," 114-115
microscopic architecture, 33-36, 35f, 36f, 37f, 38f

Retrograde axonal transport, 54-55

Rheumatoid arthritis

- clinical manifestations, 247-248
- non-vasculitic neuropathy, 264
- Riley-Day syndrome, 405
- "Roussy-Levy" variant, CMT-1, 376
- Saphenous nerve, 8
- Sarcoidosis
 - case example, 200
 - clinical manifestations, 197
 - differential diagnosis, 199-200
 - distinguishing from leprosy neuropathy, 197, 199
 - pathogenesis, 199
 - pathology, 197-199, 198f, 199f, 200f
 - usefulness of biopsy, 197
- "Sausage-like" myelin swellings. *See* Tomaculous neuropathy
- Schmidt-Lanterman clefts (incisura)
 - normal, 86-87, 87f, 88f
 - stretch artifact, 124-125, 125t
 - uncompacted myelin, 97-98, 98t, 98f
 - in Wallerian degeneration, 64
- Schwann cell/axon networks, 60-61, 61f
- Schwann cell inclusions. *See also* Inclusions
 - in neuropathies, 92-94, 101t
 - Elzholz bodies (Mu granules), 93
 - lipofuscin, 92, 93f
 - paracrystalline, 94f
 - Pi granules, 91, 92f, 93f
- Schwann cell subunit (ScSu). *See also* Denervated Schwann cell subunit
 - age-related changes, 36, 48
 - defined, 29
 - in unmyelinated fiber disease, 48, 141
- Schwann cells. *See also* Nonmyelinating Schwann cells inclusions.
 - See* Schwann cell inclusions
 - hyperchromatic nuclei, in ataxia telangiectasia, 415
 - microscopic architecture, 26-29
 - myelinating, 85
 - at node of Ranvier, 87-88
 - normal structure/function, 85
 - in peripheral nerve ischemia, 119-120
 - remyelination, 103-104
 - Schwann tube, defined, 85
- Scleroderma
 - clinical manifestations, 246
 - non-vasculitic neuropathy, 264
- Secondary amyloidosis, 295, 298-299, 300, 306
- Secondary demyelination
 - assessment on nerve biopsy, 101-102
 - clinical importance of, 102
 - in diabetes, 333, 341,
 - experimental data supporting, 101
 - in peripheral nerve ischemia, 118
 - fiber teasing, 43
- Secondary perineuritis, 201
- Segmental demyelination. *See* Demyelination
- Sensory nerve action potential (SNAP), 156, 157
- Sensory neuropathy syndrome, 474-475
- Sialidosis, 430t, 461
- Skin biopsies, 9-14
 - autonomic innervation, 17f
 - dermal myelinated axons, 11, 12f, 15f
 - diabetes, 10f, 17f
 - hairy/glabrous comparison, 11, 13f, 14f
- Sjogren syndrome. *See also* Vasculitic neuropathy
 - clinical manifestations, 247
 - non-vasculitic neuropathy, 246
 - sensory neuropathy, 474-475
- Small myelinated fibers
 - in diabetic neuropathy, 10f, 17f, 335-338
 - diameter, 26
 - fiber density and, 46t
 - in peripheral nerve ischemia, 117-119
 - selective loss, differential diagnosis, 136t
 - skin biopsies, 10f, 17f
- Sodium cyanate, neuropathy with, 357t
- Sphingolipidoses. *See also* Metachromatic leukodystrophy; Krabbe disease; Fabry disease; Farber disease; Niemann-Pick disease
 - defined, 444
 - Fabry disease, 437-444
 - Farber disease, 448-449, 49f, 450f
 - GM1 gangliosidosis, 171, 173, 192
 - GM2 gangliosidosis, 449-451
 - Krabbe disease, 436-451
 - metachromatic leukodystrophy, 429-432
 - Niemann-Pick disease, 444-447
- Spinal ganglia
 - in amyloidosis, 304
 - in paraneoplastic subacute sensory neuropathy, 311-312
 - in spinal ganglionitis, 475-476
- Spinocerebellar/cerebellar degenerations, non-Friedreich, 407
- "Stacked disc" inclusions, 434. *See also* Metachromatic leukodystrophy
- Storage diseases. *See also* Sphingolipidoses; Adrenoleukodystrophy
 - Batten-Kufs disease, 454-457
 - causing polyneuropathy, 430t
 - cerebrotendinous xanthomatosis, 459-460
 - differential diagnosis, 461, 462t
 - endoneurial cell inclusions, 146-147
 - glycogen storage diseases, 460
 - inclusions, diagnostically useful, 140t
 - mucopolysaccharidoses, 460
 - sialidosis, 430t, 461
 - Tangier disease, 430t, 457-459, 462t
 - Wolman disease, 461
- Stretch artifact, 126f
- Subacute sensory neuropathy (SSN), 311-314, 474, 475
- Subperineurial "edema". *See* Edema, subperineurial
- Sulfatides, 411-413, 89-90
- Superficial peroneal nerve, 8
- Superficial radial nerve, 8
- Sural nerve. *See also* Peripheral nerve biopsy
 - age-related changes, 36-39
 - anatomy, 8, 21-22, 22f, 23f
 - biopsy, as optimal site for, 7-8
 - biopsy, combined with muscle biopsy, 8
 - normal, quantitative data, 46t
- Suramin, neuropathy with, 357t
- Systemic inflammatory disease, non-vasculitic neuropathy 264
- Systemic lupus erythematosus. *See also* Vasculitic neuropathy
 - clinical manifestations, 247-248
 - non-vasculitic neuropathy in, 264
 - pathology, 154t, 245t, 262f, 263f
 - tubuloreticular inclusions in, 265f
- Systemic phospholipidosis, 355, 356t, 357t, 357-362, 359f, 360f, 361f, 263f. *See also* Amiodarone neuropathy
- T cells
 - in Guillain-Barre syndrome, 170
 - in infiltrative neuropathy, immunohistochemistry, 318
 - normal, in nerve, 32
 - in vasculitic neuropathy, 253
- Tangier disease, 430t, 457-459, 462t
- Taxol, neuropathy with, 357t
- Tay-Sachs disease, 449-451

- Teasing, nerve fiber. *See* Fiber teasing
- Thalidomide, neuropathy with, 152t, 298, 357t, 364
- Thallium, neuropathy and, 56, 57, 60, 61, 153t, 174, 358t
- Thiamin (B1) deficiency neuropathy, 152t, 332t, 346-347
- Thioflavin T/Thioflavin S, amyloid staining, 299
- Thiophenicol, neuropathy with, 357t
- Thyroid disease, neuropathy and, 344
- Tocopherol (vitamin E) deficiency, 348
- Tomaculous neuropathy. *See also* Hereditary neuropathy with pressure palsies
 defined, 386
 differential diagnosis, 391
 formation of, 391
- Toxic neuropathies
 axonal transport, 58
 axonopathy, 56-57
 blood-nerve barrier, 117
 differential diagnosis, 371
 epidemic inflammatory, 369
 etiologies, 356t, 357t, 358t
 general considerations, 355
 usefulness of biopsy, 371
- Toxic oil syndrome, 245, 370
- Transection, axons. *See* Wallerian degeneration
- Transthyretin, 154t, 296-297, 303f, 304f, 305f
- Tuberculoid leprosy
 clinical manifestations, 226
 pathology, 235-237, 235f, 236f, 237f
- Tubuloreticular inclusions (TRIs)
 electron microscopy, 147, 211f
 formation, 147
 in HIV infection, 211f, 213
 in hypertrophic brachial neuritis, 190, 190f, 191f
 in SLE, 265f
- Tubulovesicular structures, axons, 53-54
- "Tuffstone" inclusions, 431, 433f. *See also* Metachromatic leukodystrophy
- "Turn around defect," 57-58
- Tyrosinemia, hereditary, 416-417
- Ulcerative colitis, perineuritis in, 175, 201, 205
- Uncompacted myelin, 97-98, 98f, 98t
- Unmyelinated axons. *See* Unmyelinated fibers Unmyelinated fibers (UFs)
 assessment of pathological change, 48, 140
 identification, 28-29
 in onion bulbs, 104
 in peripheral nerve ischemia, 118, 119
 quantitative data analysis, 44-49, 46t, 47f
 selective loss of, 136t
 wallerian degeneration, 68, 68f
- Uremic neuropathy
 clinical manifestations, 345
 pathology, 345-346
 secondary demyelination in, 101
- Vacor, neuropathy and, 358t
- Vascular insufficiency, chronic, 119
- Vasculation, peripheral nerves. *See* Peripheral nerve vasculation
- Vasculitic neuropathies
 ANCA-associated microscopic polyangiitis, 247
 biopsy, muscle, 249
 case example, 264
 classification, based on vessel size, 254
- classification, etiologic, 246-248
 clinical manifestations, 246
 Churg-Strauss angiitis (eosinophilic granulomatosis with polyangiitis), 247, 257f, 258f, 262f
 CMV-related, 245t, 249, 251, 264
 connective tissue disease, 247
 in cryoglobulinemia, 153t, 154t, 245t, 249, 255
 distinction from artifact, 261
 focal ischemic injury, 117-118
 granulomatous with polyangiitis, 247
 Henoch-Schonlein purpura, 247
 HIV-associated, 210f, 214, 214f
 immunohistochemistry, 252
 isolated PNS, 246
 in leprosy, 238
 lymphomatoid granulomatosis, 264-268
 neoplasia-associated, 316
 pathology, 249-253
 polyarteritis nodosa, 246, 250f
 remote vasculitis, signs of, 255t
 SLE, 262f, 263f, 265f
 Usefulness of biopsy, 249
- Venules. *See* Peripheral nerve vasculation
- Versican, endoneurial interstitium, 33
- Very long-chain fatty acid (VLCFA) metabolism, 452-453
- Vesicular demyelination. *See* Demyelination, vesicular
- Vincristine neuropathy, 367
- Vitamin deficiency neuropathies, 152t, 332t, 346-347
 See also Thiamine deficiency; Cobalamin deficiency
- Vitamin E deficiency, 348
- Waldenstrom macroglobulinemia, 154t, 273, 274t, 274
- Wallerian degeneration
 blood-nerve barrier, 115-116
 endoneurial changes, 68-69
 mast cell proliferation, 31
 mechanisms, 72-73
 morphology, 63-72, 65f, 66f, 67f, 68f, 69f, 70f, 71f
 myelin degradation, 64, 66
 peripheral nerve ischemia, 118, 119
 regeneration, 75-80
 Schmidt-Lanterman cleft alterations, 86
- Wegener granulomatosis, 247
- Weibel-Palade bodies, 112, 115f
- Widely spaced myelin, 97-100, 99t, 99f, 280f
- Wolman disease, 430t, 461
- X-linked bulbospinal neuropathy, Xeroderma pigmentosum 476
- X-linked CMT 384
- Xanthomatous neuropathy in primary biliary cirrhosis, 346
- Xeroderma pigmentosum (XP), 415
- "Zebra" bodies, 432, 434, 441, 448, 451, 460,
"Zebra body-like" inclusions, 91, 447
- Zonulae occludens, perineurium, 22, 25f